Michael Chao
, Director
biomedical
BioAnalytix
Japan
Biography
Michael Chao, MD is a Managing Director of MAL Investment Company, an investment group dedicated to providing capital to companies developing promising technologies and/or offering novel services to address unmet needs. As a financier, Dr. Chao concentrates on investments that build preeminent healthcare companies. He has been involved in investments with Ovagene Oncology, Tanvex BioPharma, TenNor Therapeutics, EarLens, and Ansun Biopharma. He serves on the board of MidLabs, and served on the board of Owl Biomedical through its successful sale to Miltenyi Biotec. Furthermore, Dr. Chao maintains a direct link to the health community as a staff physician at the US Department of Veterans Affairs healthcare system, providing medical and surgical care for veterans and combat veterans from current and prior military conflicts. With this position, Dr. Chao is able to stay current with medical practices and advancements. Dr. Chao also serves on Children’s Hospital of Orange County (CHOC) Foundation Board, where he chairs the Transformational Philanthropic Venture Funding Committee, which supports innovative ideas in pediatric health. Dr. Chao received his MD from University of California, Irvine and his BA in Biology from the University of Pennsylvania. He has authored several articles with other physicians, and has presented medical findings at various societal meetings.
Research Interest
biomedical,bioinformatics
